找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Disease Recurrence After Liver Transplantation; Natural History, Tre Paul J. Thuluvath Book 2016 Springer Science+Business Media New York 2

[復(fù)制鏈接]
樓主: otitis-externa
21#
發(fā)表于 2025-3-25 04:28:42 | 只看該作者
Cholangiocarcinoma,modal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric
22#
發(fā)表于 2025-3-25 07:45:25 | 只看該作者
Recurrent Non-hepatic and De Novo Malignancies After Liver Transplantation,rson-years calculated by adding survival of each patient) are compared with epidemiological data for each cancer type. This method provides the precise incidence of cancer post-LTx compared to general population. Rates of malignancy increase in proportion to age at transplant and length of follow-up
23#
發(fā)表于 2025-3-25 13:18:16 | 只看該作者
24#
發(fā)表于 2025-3-25 17:31:15 | 只看該作者
25#
發(fā)表于 2025-3-25 22:13:09 | 只看該作者
Ivica Milevski,Ekaterina Ivanovaotentially reverses the consequences and complications of the initial abnormalities depending on the severity of the complications, reversibility, and time interval between the diagnosis of the problem and replacement of the liver.
26#
發(fā)表于 2025-3-26 00:09:16 | 只看該作者
27#
發(fā)表于 2025-3-26 04:47:32 | 只看該作者
28#
發(fā)表于 2025-3-26 11:05:50 | 只看該作者
vered.As there is a high incidence of disease recurrence after liver transplantation, this volume is designed around the need for a reference text dealing exclusively with this problem. The book places special emphasis on pre- and post-transplant predictors of recurrence, severity assessment, prophy
29#
發(fā)表于 2025-3-26 14:10:09 | 只看該作者
30#
發(fā)表于 2025-3-26 18:50:32 | 只看該作者
Ivica Milevski,Ekaterina Ivanovaion resulting in cardiovascular events—which is considered today the leading cause of death following liver transplantation in NASH recipients, surpassed only by sepsis. Patients with NASH cirrhosis should be carefully evaluated and selected for liver transplantation, and metabolic risk factors should be treated aggressively.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 21:02
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
河曲县| 肥西县| 唐海县| 集安市| 竹山县| 喀喇| 惠安县| 罗源县| 广饶县| 芦溪县| 额尔古纳市| 井陉县| 南江县| 行唐县| 襄城县| 封丘县| 五河县| 贵定县| 周口市| 鄂托克旗| 左云县| 隆安县| 泗阳县| 姚安县| 彭阳县| 全南县| 乌兰察布市| 木里| 铅山县| 静乐县| 盐城市| 比如县| 登封市| 江城| 仪征市| 建始县| 绥化市| 汉寿县| 石泉县| 会宁县| 三门县|